Home
/ Onco360
/ Competitors

Onco360 Competitors and Similar CompaniesClear all

Onco360's competitors and similar companies include Siloam, Orexo, Celentyx and Chemi Darou.

	Onco360 Onco360 (also known as OncoMed Specialty) is a provider of oncology pharmacy services.	Siloam Siloam is a healthcare provider.	Orexo Orexo, a specialty pharmaceutical company, engages in the development and commercialization of drugs.	Celentyx Celentyx is a human immune system focused company specializing in immuno-oncology, inflammation, and autoimmunity in vitro assays.	Chemi Darou Chemi Darou is a company that provides pharmaceutical products and services.
Founding Date	Founding Date 2003	Founding Date 1996	Founding Date 1995	Founding Date 2007	Founding Date 1981
Type	Type Subsidiary	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare drug monitoring oncology pharma pharmacy	Tags Healthcare oncology pharmacy	Tags Healthcare drug development oncology pharma pharmacy	Tags Healthcare biotech drug monitoring oncology pharma	Tags Healthcare drug monitoring pharma pharmacy
Locations	Locations Louisville, US HQ Buffalo, US Houston, US New Hyde Park, US Scottsdale, US Waltham, US Woodridge, US	Locations ID HQ	Locations Uppsala, SE HQ Uppsala, SE Morristown, US	Locations Birmingham, GB HQ Oxford, GB	Locations Tehran, IR HQ
Employees	Employees 5791% increase	Employees 14,616	Employees 110	Employees 12	Employees 55
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) Rp12.8t (FY, 2025)	Revenue (est.) kr26m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods Rp7.7t (FY, 2025)	Cost of goods kr14.5m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit Rp5.2t (FY, 2025)	Gross profit kr18m (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income Rp1.2t (FY, 2025)	Net income (kr403.3m) (FY, 2025)	Net income N/A	Net income N/A